Cancer remains one of the leading causes of death across the world. Hence, significant efforts are still being made to discover anticancer drugs for the treatment of cancer patients with critical needs. Recent studies suggest that new bioactive compounds with a wide range of chemical and functional properties can be identified from the marine microbial realm to treat cancer-like life-threatening diseases. Paenibacillus lentimorbus SAGM 3 is a Gram-positive, facultative anaerobic, and endospore-forming bacterium that has been under-evaluated for its biomedical significance. On account of a unique exploration, this study purified and structurally characterized an anticancer compound from the cell-free extract of marine-derived P. lentimorbus SAGM 3 against MCF-7 cells and MDA-MB-231 breast cancer cells. After performing Fourier transform infrared, nuclear magnetic resonance, gas chromatography, and mass spectrometry (MS)/MS analysis, the chemical structure of the purified anticancer compound was confirmed as Chojalactone C ((3R)- 3-hydroxy-4-methylidene-3-[(2E,4E,6E)-octa-2,4,6-trienoyl] oxolan-2-one). Interestingly, the purified Chojalactone C revealed complete inhibition of MCF7 and MDA-MB-231 breast cancer cell lines at 800 μg/ml and 700 μg/ml, respectively. This is the first report of Chojalactone C synthesis from a bacterium, which enhances its possibilities of production and purification for future clinical trials intended to assess its therapeutic significance.
Key words: Marine P. lentimorbus; Anticancer; Chojalactone C; MCF7; MDA-MB-231
|
